Phase 2 study of nilotinib as third‐line therapy for patients with gastrointestinal stromal tumor - Concepedia

Concepedia

Publication | Open Access

Phase 2 study of nilotinib as third‐line therapy for patients with gastrointestinal stromal tumor

DOI Full Paper Access

85

Citations

25

References

2011

Year

Akira Sawaki, Toshirou Nishida, Toshihiko Doi, Yasuhide Yamada, Yoshito Komatsu, Tatsuo Kanda, Yoshihiro Kakeji, Yusuke Onozawa, Makoto Yamasaki, Atsushi Ohtsu

Abstract

These results suggest that nilotinib is generally well tolerated and has encouraging antitumor activity in patients with GIST who failed both imatinib and sunitinib.

References

	Year	Citations
Gain-of-Function Mutations of c- <i>kit</i> in Human Gastrointestinal Stromal Tumors Seiichi Hirota, Koji Isozaki, Y Moriyama, Science	1998	4.4K
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors George D. Demetri, Margaret von Mehren, Charles D. Blanke, New England Journal of Medicine	2002	4.4K
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett, The Lancet Gastrointestinal OncologyMedicinePathologyColorectal CancerCancer Treatment	2006	2.6K
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor Michael C. Heinrich, Christopher L. Corless, George D. Demetri, Journal of Clinical Oncology	2003	2.3K
<i>PDGFRA</i> Activating Mutations in Gastrointestinal Stromal Tumors Michael C. Heinrich, Christopher L. Corless, Anette Duensing, Science	2003	2.3K
Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation Cristina R. Antonescu, Peter Besmer, Tianhua Guo, Clinical Cancer Research	2005	826
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor Michael C. Heinrich, Robert G. Maki, Christopher L. Corless, Journal of Clinical Oncology	2008	799
Active transport of imatinib into and out of cells: implications for drug resistance Julia Thomas, Lihui Wang, Richard E. Clark, Blood	2004	640
OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib Deborah L. White, Verity A Saunders, Phuong Dang, Blood	2006	430
Textbook of Medical Physiology &NA; &NA; The American Journal of the Medical Sciences Physiological PrincipleOrgan PhysiologyMedical PhysiologyHealth SciencesPhysiology	1957	395

Page 1